Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Spitthöver R, Röseler T, Julius U, Heigl F, Schettler VJJ, Kühn R, Leebmann J, Raabe A, Knittel M, Schürfeld C, Moesenthin M, Bernhardt WM, Röseler E, Ketteler M, Heibges A, Klingel R.
Spitthöver R, et al. Among authors: heibges a.
J Clin Apher. 2019 Aug;34(4):423-433. doi: 10.1002/jca.21695. Epub 2019 Feb 28.
J Clin Apher. 2019.
PMID: 30817043